Research programme: farnesyl transferase inhibitors - MerckAlternative Names: Farnesyl transferase inhibitors research programme - Merck
Latest Information Update: 12 Feb 2008
At a glance
- Originator Merck & Co
- Mechanism of Action Farnesyltranstransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Feb 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 04 May 2000 New profile
- 04 May 2000 Preclinical development for Cancer in USA (Unknown route)